Effects of Paroxetine on Cardiovascular Function in Septic Patients

Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude

Status and phase: Enrolling; Phase 2

Conditions: Septic Shock; Sepsis

Treatments: Drug: Paroxetine

Study type: Interventional

Funder types: Other

Identifiers

NCT05725837

Paroxetine

Details and patient eligibility

About

It is known that septic shock is characterized by arterial hypotension, decreased peripheral vascular resistance and hyporeactivity to vasoconstrictor agents, with NO being an important mediator of this organ dysfunction. Data in the literature have shown that hyporeactivity to catecholamines is associated with a decrease in the density of α and ß receptors in the aorta and heart, respectively, as well as an increase in GRK2 levels and that NO contributes to the increase of this kinase in sepsis .

Based on this, it is hypothesized that cardiac dysfunction and decreased peripheral vascular resistance observed in sepsis may result from an increase in GRK2 activity and/or expression and its inhibition may be a relevant therapeutic target in septic shock patients. Based on this line, a measurable clinical benefit of paroxetine through the regulation of GRK2 expression in patients with septic shock is postulated.

Enrollment: 92 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient over 18 years of age;
• Patient diagnosed with septic shock for less than 48 hours and using a minimum dose of noradrenaline (0.01 mcg/kg/min);
• Patients and/or legal guardians who consented to participate in the study through the free and informed consent term before randomization.

Exclusion criteria

• Pregnant women;
• Patients with inability to use the gastrointestinal tract;
• Patients with known intolerance to paroxetine and/or fluoxetine;
• Patients on concomitant use of medications that may potentiate the occurrence of serotonin syndrome (tramadol, citalopram, escitalopram, sertraline, desvenlafaxine, venlafaxine, duloxetine, sibutramine, bupropion, amitriptyline, nortriptyline, lithium);
• Patients in end-of-life care or with an expected survival of less than 24 hours at the time of eligibility

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

92 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

40mg, single dose a day, by mouth or enteric tube

Treatment:

Drug: Paroxetine

Paroxetine

Experimental group

Description:

40mg, single dose a day, by mouth or enteric tube

Treatment:

Drug: Paroxetine